The removal of Marty Makary from the FDA is expected to result in lighter enforcement on compounded GLP-1s and telehealth services, which is viewed as a positive catalyst for HIMS. This regulatory shift directly benefits the HIMS business model compared to competitors LLY (Eli Lilly) and NVO (Novo Nordisk). The market is anticipated to react positively in the short term following previous stock drops caused by the initial February 2026 crackdown.